Buy Ilumya (tildrakizumab) Online For Sale
DISEASE INDICATIONS: Psoriasis
MANUFACTURER: Almirall, S.A.
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Ilumya (tildrakizumab) is a biologic medication used to treat moderate-to-severe plaque psoriasis in adults. It works by blocking the activity of the protein IL-23, which reduces inflammation and scaling in the affected skin.
Ilumya (tildrakizumab) is a biologic medication used for the treatment of moderate-to-severe plaque psoriasis in adults. It is a selective interleukin-23 (IL-23) inhibitor that works by blocking the activity of IL-23, a protein that plays an important role in the development of psoriasis. By inhibiting the activity of this protein, tildrakizumab reduces the inflammation and scaling that are hallmarks of this autoimmune skin condition.
Plaque psoriasis is a chronic autoimmune skin condition characterized by red, scaly, and raised patches on the skin that may itch, burn, or bleed. It is caused by an overactive immune system that leads to the abnormal growth of skin cells. Symptoms typically first appear in late childhood or young adulthood and can be triggered by a variety of factors, including stress, infection, or injury.
Ilumya is administered as an injection every 12 weeks after an initial dose at week 0 and is available in pre-filled syringes or prefilled pens. The recommended dosage is 100 mg. Patients should receive training before self-injecting for the first time and dispose of used needles and syringes safely.
Ilumya has been shown to be effective in treating plaque psoriasis in numerous clinical studies. In one double-blind, placebo-controlled trial of 1,259 participants, over 60% of patients treated with tildrakizumab achieved clear or almost clear skin, compared to about 6% of patients treated with placebo. Tildrakizumab also demonstrated longer periods of time until the onset of a relapse of psoriasis symptoms compared to placebo.
Despite being an effective treatment option, Ilumya is not without side effects. The most common side effects associated with the use of the medication include upper respiratory infections, injection site reactions, and diarrhea. Serious side effects such as infections, malignancies, and hypersensitivity reactions have been reported, and all patients should be closely monitored for these and other potential reactions.
Ilumya should not be used in patients with a history of severe hypersensitivity reactions, such as anaphylaxis, to tildrakizumab or any of its components. Patients with active tuberculosis or who have recently been treated for tuberculosis or other serious infections should also avoid treatment with Ilumya. The medication should be used with caution in patients with a history of malignancies.
In summary, Ilumya (tildrakizumab) is a biologic medication used for the treatment of moderate-to-severe plaque psoriasis in adults. It is a selective IL-23 inhibitor that works by blocking the activity of the protein IL-23 and reducing inflammation and scaling in psoriasis patients. Ilumya is administered through an injection every 12 weeks after an initial dose at week 0. The medication has been shown to be effective in treating plaque psoriasis, but it is not without side effects, including upper respiratory infections, injection site reactions, and diarrhea. Patients should be closely monitored for serious side effects, including infections, malignancies, and hypersensitivity reactions.
One syringe of 100 mg/ml